NPC1 and Niemann-Pick disease type C: To distinguish between these possibilities, we tested whether HβCD, a cyclic oligosaccharide that triggers cholesterol release from the endo-lysosomal compartment [49,50] and has been used to treat persons with Niemann-Pick disease type C [51,52], for the capacity to overcome the effects of NPC1 deficiency on reovirus infection.